modelS01BA02
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Hydrocortisone | |
| ATC code: | S01BA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 16 | L/hr |
| other parameters in model implementation | ||
Hydrocortisone is a corticosteroid hormone (glucocorticoid) used to treat inflammation, allergic reactions, adrenal insufficiency (such as Addison's disease), and certain eye disorders. It is commonly approved and used today both systemically and in topical or ophthalmic preparations.
Pharmacokinetics
Pharmacokinetic parameters were estimated for healthy adult subjects following single intravenous and oral doses.
References
Hamitouche, N, et al., & Laviolle, B (2017). Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. The AAPS journal 19(3) 727–735. DOI:10.1208/s12248-016-0041-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28083797
Vincze, I, et al., & Kopitkó, C (2022). Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). Journal of clinical medicine 11(14) –. DOI:10.3390/jcm11144140 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35887904
Knych, HK, et al., & Kass, PH (2019). Pharmacokinetics of intravenous flumetasone and effects on plasma hydrocortisone concentrations and inflammatory mediators in the horse. Equine veterinary journal 51(2) 238–245. DOI:10.1111/evj.13002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30080272
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)